BCX4430
| Structural formula | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||
| General | ||||||||||
| Surname | BCX4430 | |||||||||
| other names |
(2 S , 3 S , 4 R , 5 R ) -2- (4-Amino-5 H -pyrrolo [3,2- d ] pyrimidin-7-yl) -5-hydroxymethylpyrrolidin-3,4-diol ( IUPAC ) |
|||||||||
| Molecular formula | C 11 H 15 N 5 O 3 | |||||||||
| External identifiers / databases | ||||||||||
|
||||||||||
| properties | ||||||||||
| Molar mass | 265.27 g · mol -1 | |||||||||
| safety instructions | ||||||||||
|
||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||
BCX4430 (synonym immucillin-A ) is an experimental antiviral agent from the group of adenosine - analogs .
development
BCX4430 was originally developed as a drug against the hepatitis C virus , but later against filoviruses such as the Ebola virus or the Marburg virus , by BioCryst Pharmaceuticals with financial support from NIAID . It is also effective against various RNA viruses , e.g. B. bunyaviruses , arenaviruses , paramyxoviruses , coronaviruses and flaviviruses . In animal experiments with primates, BCX4430 protected against infection with the Ebola virus when administered up to 48 hours after infection.
In the course of the Ebola virus epidemic in 2014 , an accelerated approval process was initiated for BCX4430. The European Medicines Agency's Committee for Medicinal Products for Human Use announces the publication of its assessment for early 2016.
properties
BCX4430 inhibits RNA polymerase . The water-soluble substance is chiral and is obtained as a pure stereoisomer.
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ a b TK Warren, J. Wells, RG Panchal, KS Stuthman, NL Garza, SA Van Tongeren, L. Dong, CJ Retterer, BP Eaton, G. Pegoraro, S. Honnold, S. Bantia, P. Kotian, X Chen, BR Taubenheim, LS Welch, DM Minning, YS Babu, WP Sheridan, S. Bavari: Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. In: Nature . Volume 508, number 7496, April 2014, pp. 402-405, doi : 10.1038 / nature13027 , PMID 24590073 .
- ↑ Kamat SS, Burgos ES, Raushel FM. Potent inhibition of the CP lyase nucleosidase PhnI by Immucillin-A triphosphate. Biochemistry . 2013 Oct 22; 52 (42): 7366-8. doi : 10.1021 / bi4013287 PMID 24111876 .
- ^ E. De Clercq: Ebola virus (EBOV) infection: therapeutic strategies. In: Biochemical Pharmacology . [Electronic publication before going to press] December 2014, doi : 10.1016 / j.bcp.2014.11.008 , PMID 25481298 .
- ↑ G. Wong, X. Qiu, GG Olinger, GP Kobinger: Post-exposure therapy of filovirus infections. In: Trends in microbiology. Volume 22, number 8, August 2014, pp. 456-463, doi : 10.1016 / j.tim.2014.04.002 , PMID 24794572 .
- ↑ JG Julander, S. Bantia, BR Taubenheim, DM Minning, P. Kotian, JD Morrey, DF Smee, WP Sheridan, YS Babu: BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. In: Antimicrobial Agents and Chemotherapy . Volume 58, Number 11, November 2014, pp. 6607-6614, doi : 10.1128 / AAC.03368-14 , PMID 25155605 .
- ↑ Paul Rodgers: Biowar Lab Helping To Develop Treatment For Ebola . In: Forbes Magazine , April 8, 2014.
- ↑ Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016 , 29 January 2016.
